HUE025086T2 - ERB-B1 receptorra irányuló gyógyászati készítmények - Google Patents

ERB-B1 receptorra irányuló gyógyászati készítmények Download PDF

Info

Publication number
HUE025086T2
HUE025086T2 HUE03757931A HUE03757931A HUE025086T2 HU E025086 T2 HUE025086 T2 HU E025086T2 HU E03757931 A HUE03757931 A HU E03757931A HU E03757931 A HUE03757931 A HU E03757931A HU E025086 T2 HUE025086 T2 HU E025086T2
Authority
HU
Hungary
Prior art keywords
receptor
antibody
antibodies
erbb
receptors
Prior art date
Application number
HUE03757931A
Other languages
English (en)
Inventor
Hans-Georg Kreysch
Juergen Schmidt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUE025086T2 publication Critical patent/HUE025086T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Claims (2)

  1. pRB_m ΚΓΕΓΓ««Λ IRANWI.Ó ew'XJVAsZAn KÉSZÍTMÉNYEK SxabiKJairaS i&amp;m9*** .. , .. ««wly tmirUmaz fa) eiií^ysg-xnMekMá:. ErbBl «-ce^^nnoie· ^ ,.r xwsb« **« i«*> k«IKhite. «ra,to.»«» »*>* ·*»^«*-* · .....,,^',Κ,Ι,.,,Γ^.,,,-Μ,Κν.'-^·- a.Yrta^wiEU^T.H.x.'v-a.k. issxieiy ugysatfcfOtt hri?»1 ..... Mar:';:-.:: .. .. KSkMaikekstamima^ : : ; ::: ,:::::::::::: :::: , ,, , ,, h;si.,.„-»i, '1 a t »r· v>.\k."!i,., ,1 ,,e, -·.:·· a··..... : * :::: ..0 . ., ...... . In) m '*:«*' Erl>31 "·'*" MK’lloni'"·1® Ψ» !aia,r'M'' ' ‘ , "·* . - -«* Μ * -^ .·. * > Μ. , -.,-,11,-I--,·,,-,, ιι-,Μ- , ^ , Μ. ρ·„·ί;>:.·α1: Κ,-ν,.η,·|:. *1 « U.W..,.*, --¾ ·< ^00.1,. 0-|-,«- ^,®; Wait kí«M. !y*«* tivpkrtm. *««·»*»,ό®«1»»Λ i-.Mi.aol, Itaj* ; „ χ , 1 X- »'>" ' ' -'Χ-''1' 1-61-..-,.,10-:,, V1 (. 1 -ΓΟ.ι— ο *,ϊ.· Μ·'--' -!'Μ-" ·> '-S'-' ,: ,., ,,, ..„ ... -,. atal,... ... -·.-> :.:::,:: Μ -<' >-'- ®δ Κν--.α,« or-·.-,-1,-.1 1-,-1.-.1.- ..-1.--1- Yt Π,-ο,-ο-,^-ΌΟ-οΙ,. .«..la,.,· -, Lf. .„---I .χ.,.|..'„,« a <ii> <#*&amp; c^mi% :»Iy ««**»·> B»i mm*******»*» #«** *»**- KSW*»specifikus cDitMxa »«*» «W ”>to«iikοί«:*ΐΛΠ:><·»»1« rnmlnm,»i»i , ., .K—- -,.-.---, t --' — -'1 - - -· -'-" ' V-'-' '""Ί'··Κ J., ,· ,U.™.*-mA-k»lA l»S.‘i*i> -Υνί.-- k»,-,R :01-661 -v-W keiül Μ» nns xM-v, ,i:5>d-Ι«.ν h'-ooKYs kg;»\h,i ' J ,vn,k vnii ώ \ΐχ;ο-'.>-οίπμ» " ^ arteioxa?,- 7.Λ 6, igtoypmt sterinsi gyógyászati késztet, stndy tárház továbbá szexi tanúrnazö ?.!.i!!'v;'.«s'lík cso-sssg-'!·. 8 X\ ,^T vxnví ινίιντΐι WxvMs. MiM ,s k -1 - v * ^ - -y ·*Γ^ ‘
  2. 5 -X k ^vsv--v k^íinb - -- &amp; >1 -= Kru'íenru··* V -,: o - í ín \ ο \ - o i -. s"!,in ί«Η\νΚΛ i-'O ! Ciíx'' 1 'lvX ' K u Itt V - UÍO-Οΐοο-,Μ V,» 1.Γ1 ΙΛ-Χ-Ο4',^ t-ozi'k« Jvt -'- "-· -Λ SXoV^to5 «X Hite-, X Kv ι,'Χΐϊίι'ί'ΛιΜ'Ιί τ:ϊ-χ\ 1Y,- kN' '- '-íN.isVit;·-'; :\l '--zu Κ-Γ-Í.i' x iV'-'t'.l-X-T'!' ” τ'· ' ot Ό-ιΛ οί'< !κιΠ U.Aü Mi), igecypoosok \μχϊχι?&amp;&amp;*' κφ^οζοϋ gyógyiisasi kés*ift«éoy v^y gyögyászatt fcesje: -kUl ^ vé!h! tütm^Í· í2 x H ÍY,:n^->tk xagv jí '« &amp;&amp;a3ma^«, a ttanor mciiták; pto^tórák, fvj*nyok SCi-C vagy hasnyátatirigyxák.
HUE03757931A 2002-10-10 2003-10-09 ERB-B1 receptorra irányuló gyógyászati készítmények HUE025086T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02022390 2002-10-10
EP02022389 2002-10-10

Publications (1)

Publication Number Publication Date
HUE025086T2 true HUE025086T2 (hu) 2016-02-29

Family

ID=32095025

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE03757931A HUE025086T2 (hu) 2002-10-10 2003-10-09 ERB-B1 receptorra irányuló gyógyászati készítmények

Country Status (19)

Country Link
US (2) US7638125B2 (hu)
EP (2) EP1549345A1 (hu)
JP (3) JP2006505546A (hu)
KR (2) KR101088661B1 (hu)
CN (1) CN1703243B (hu)
AU (2) AU2003273964B2 (hu)
BR (2) BR0315123A (hu)
CA (2) CA2501818C (hu)
CY (1) CY1116167T1 (hu)
DK (1) DK1549344T3 (hu)
ES (1) ES2533963T3 (hu)
HK (2) HK1081448A1 (hu)
HU (1) HUE025086T2 (hu)
MX (2) MXPA05003796A (hu)
PL (2) PL210545B1 (hu)
PT (1) PT1549344E (hu)
RU (2) RU2349340C2 (hu)
SI (1) SI1549344T1 (hu)
WO (2) WO2004032960A1 (hu)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
HUP0201480A3 (en) * 1999-05-14 2009-03-30 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PT2163256E (pt) 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
JP2006505546A (ja) * 2002-10-10 2006-02-16 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 二重特異性抗ＥｒｂＢ抗体および腫瘍治療でのその使用
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DK1735348T3 (da) * 2004-03-19 2012-07-16 Imclone Llc Humant anti-epidermalt vækstfaktorreceptorantistof
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
CN101426815A (zh) * 2005-12-06 2009-05-06 杜门蒂斯有限公司 具有表皮生长因子受体和/或血管内皮生长因子结合特异性的配体及其使用方法
US20090214541A1 (en) * 2006-01-04 2009-08-27 L'instut National De La Sante Et De La Recherche Medicale Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies
US20110165150A1 (en) * 2006-01-18 2011-07-07 Merck Patent Gmbh Isolated organ perfusion combination therapy of cancer
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
WO2007123661A2 (en) 2006-03-31 2007-11-01 Massachusetts Institute Of Technology Treatment of tumors expressing mutant egf receptors
CA2652926A1 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
CA2670315A1 (en) 2006-11-21 2008-11-20 The Regents Of The University Of California Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
CN101711284A (zh) 2007-01-25 2010-05-19 达娜-法勃肿瘤研究所 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
CN104151430A (zh) 2007-03-01 2014-11-19 西福根有限公司 重组抗表皮生长因子受体抗体组合物
AU2013200209B9 (en) * 2007-03-01 2015-07-09 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US20110256142A1 (en) 2007-09-06 2011-10-20 Genmab A/S Novel methods and antibodies for treating cancer
JP2010540578A (ja) * 2007-10-02 2010-12-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 結晶ｅｇｆｒ−マツズマブ複合体、及び、得られたそれらのマツズマブ模倣物
WO2009070753A2 (en) * 2007-11-28 2009-06-04 The Scripps Research Institute Bivalent single chain fv antibody compositions that specifically bind to integrin receptor on a metastatic cell in a mammalian subject
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
EP2331577B1 (en) * 2008-08-29 2017-06-07 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
CA2779436A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
WO2010112193A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
JP5616428B2 (ja) * 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
EP3235504B1 (en) * 2009-10-14 2019-09-18 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
JP6184695B2 (ja) * 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
JP2013533211A (ja) 2010-05-04 2013-08-22 メリマック ファーマシューティカルズ インコーポレーティッド 上皮成長因子受容体（ｅｇｆｒ）に対する抗体およびその使用
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US9464136B2 (en) * 2010-08-20 2016-10-11 Massachusetts Institute Of Technology Antibody-based constructs directed against tyrosine kinase receptors
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
PT2668209T (pt) 2011-01-24 2021-04-07 Gilead Sciences Inc Anticorpos seletivos para células que apresentam egfr em alta densidade
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
JP6325527B2 (ja) * 2012-05-02 2018-05-16 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ ヒト化ｐａｎ−ｈｅｒ抗体組成物
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
US20150266970A1 (en) * 2012-10-24 2015-09-24 Yeda Research And Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EA038918B1 (ru) 2013-03-15 2021-11-09 Зинджения, Инк. Пептид, связывающий рецептор эпидермального фактора роста, мультиспецифические комплексы, содержащие пептид и антитела, и их применение
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
CN105940113A (zh) 2013-11-13 2016-09-14 酵活有限公司 靶向egfr和/或her2的单价抗原结合构建体及其用途
AU2014357292B2 (en) 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
CA2965362A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
CA2965521A1 (en) * 2014-10-31 2016-05-06 Baylor College Of Medicine Survivin specific t-cell receptor targeting tumor but not t cells
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
SG10202008325XA (en) * 2015-10-02 2020-09-29 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
CN108139394B (zh) * 2015-10-02 2020-10-30 豪夫迈·罗氏有限公司 用于确定同时结合的基于细胞的fret测定法
EP3565847A1 (en) * 2017-01-09 2019-11-13 Biomunex Pharmaceuticals A polypeptide linker for preparing multispecific antibodies
CN117003887A (zh) 2017-04-03 2023-11-07 豪夫迈·罗氏有限公司 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
BR112019019821A2 (pt) 2017-04-05 2020-04-22 Hoffmann La Roche anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
EP0531472B1 (en) * 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1994000136A1 (en) 1992-06-30 1994-01-06 Oncologix, Inc. A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING
JPH05320513A (ja) * 1992-05-26 1993-12-03 Toray Dow Corning Silicone Co Ltd 粘土状オルガノポリシロキサン組成物
CN101073668A (zh) * 1999-04-28 2007-11-21 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
WO2001090192A2 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2002066058A1 (en) * 2001-02-19 2002-08-29 Merck Patent Gmbh Modified anti-egfr antibodies with reduced immunogenicity
JP2006505546A (ja) * 2002-10-10 2006-02-16 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 二重特異性抗ＥｒｂＢ抗体および腫瘍治療でのその使用

Also Published As

Publication number Publication date
DK1549344T3 (en) 2015-04-07
AU2003273964B2 (en) 2009-11-19
CY1116167T1 (el) 2017-02-08
EP1549345A1 (en) 2005-07-06
ES2533963T3 (es) 2015-04-16
WO2004032961A1 (en) 2004-04-22
MXPA05003795A (es) 2005-06-08
RU2005114480A (ru) 2006-02-10
PT1549344E (pt) 2015-04-15
MXPA05003796A (es) 2006-02-22
HK1081449A1 (en) 2006-05-19
US7226592B2 (en) 2007-06-05
CN1703243A (zh) 2005-11-30
BR0315123A (pt) 2005-08-16
AU2003276084B2 (en) 2009-07-09
RU2005114482A (ru) 2006-01-27
PL374587A1 (en) 2005-10-31
AU2003273964A1 (en) 2004-05-04
CA2501818A1 (en) 2004-04-22
JP2006505545A (ja) 2006-02-16
KR101088661B1 (ko) 2011-12-01
CA2501821A1 (en) 2004-04-22
JP5179702B2 (ja) 2013-04-10
CA2501821C (en) 2012-08-14
WO2004032960A1 (en) 2004-04-22
CN1703243B (zh) 2011-05-04
RU2354402C2 (ru) 2009-05-10
CA2501818C (en) 2012-03-27
SI1549344T1 (sl) 2015-05-29
AU2003276084A1 (en) 2004-05-04
EP1549344B1 (en) 2015-01-07
KR20050062612A (ko) 2005-06-23
JP2010280727A (ja) 2010-12-16
US20060002920A1 (en) 2006-01-05
HK1081448A1 (en) 2006-05-19
US7638125B2 (en) 2009-12-29
KR20050057631A (ko) 2005-06-16
EP1549344A1 (en) 2005-07-06
PL374586A1 (en) 2005-10-31
BR0315117A (pt) 2005-08-16
RU2349340C2 (ru) 2009-03-20
JP2006505546A (ja) 2006-02-16
PL210545B1 (pl) 2012-01-31
US20060165685A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
DK1549344T3 (en) PHARMACEUTICAL COMPOSITION FOR ERB-B1 RECEPTORS
AU2002315306B2 (en) Combination therapy using anti-EGFR antibodies and anti-hormonal agents
CA2436326C (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
AU2002315306A1 (en) Combination therapy using anti-EGFR antibodies and anti-hormonal agents
AU2002219221A1 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
BRPI0620888A2 (pt) terapia de combinação usando anticorpos anti-egfr e anti-her2
ZA200503706B (en) Pharmaceutical compositions directed to Erb-B1 receptors